Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,452,000
+30,000 (2.11%)
Nov 3, 2026, 3:30 PM KST
Samsung Biologics Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Samsung Biologics stock has a consensus rating of "Buy" and an average price target of ₩1,879,148. The average 1-year stock price forecast is 29.42% higher than the current stock price, while the lowest is ₩1,350,000 (-7.02%) and the highest is ₩2,200,000 (+51.52%).
Price Target: ₩1,879,148 (+29.42%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Samsung Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 13 | 15 | 14 | 15 | 14 |
| Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Hold | 0 | 0 | 0 | 1 | 1 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 25 | 25 | 26 | 27 |
Financial Forecast
Revenue This Year
5.59T
from 4.56T
Increased by 22.68%
Revenue Next Year
6.45T
from 5.59T
Increased by 15.42%
EPS This Year
38.51K
from 26.63K
Increased by 44.61%
EPS Next Year
46.60K
from 38.51K
Increased by 21.03%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.